![]() Further complications can be avoided with early diagnosis and appropriate care. The cause of death worldwide is kidney disease, specifically Chronic Kidney Disease (CKD). Clinical laboratories test for creatinine to measure Glomerular Filtration Rate (GFR) and Blood Urea Nitrogen (BUN) to assess kidney health and function. An organic acid in muscles called creatine is broken down into creatinine, an endogenous waste product. The need for quick diagnostic tests to measure creatinine levels is being driven by the rapidly rising prevalence of diabetes, which has a detrimental effect on kidney function, the rising prevalence of chronic kidney diseases among the aging population, and the rising number of patients with kidney cancer, glomerulonephritis, and renal failures, among other conditions. Rapid diagnostic methods and procedures to assess creatinine levels in blood and urine are becoming increasingly in demand, causing the market to expand. The rising kidney-related problems are driving market CAGR for Creatinine Tests. Growing kidney related problems is driving the market growth. ![]() Source: Secondary Research, Primary Research, MRFR Database and Analyst Review Growing elderly populations, medical technology advances, and government spending on healthcare to combat the development of renal disorders are the key market drivers enhancing the market growth. The Creatinine Test market industry is projected to grow from USD 1.042 Billion in 2023 to USD 3.36 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.80% during the forecast period (2023 - 2032).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |